Publications by authors named "Carol Boss"

Claim this Profile
A
A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers.
Steven J Lemery, Matthew M Hsieh, Aleah Smith, Sheila Rao, Hanh M Khuu, Carol Boss

Br J Haematol· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.
Katayoun Rezvani, Agnes S M Yong, Stephan Mielke, Behnam Jafarpour, Bipin N Savani, Carol Boss

Haematologica· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.
Elaine M Sloand, Matthew J Olnes, Aarthie Shenoy, Barbara Weinstein, Carol Boss

J Clin Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Georg Aue, Ndegwa Njuguna, Xin Tian, Susan Soto, Thomas Hughes, Carol Boss

Haematologica· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study.
Phillip Scheinberg, Colin O Wu, Olga Nunez, Priscila Scheinberg, Carol Boss

Haematologica· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
Katayoun Rezvani, Agnes S M Yong, Stephan Mielke, Bipin N Savani, Laura Musse, Carol Boss

Blood· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.
Patrick F Fogarty, Ruth Seggewiss, Donna Jo McCloskey, Carol A Boss, Cynthia E Dunbar

Haematologica· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome.
Scott R Solomon, Bipin N Savani, Richard Childs, Aldemar Montero, Carol Boss

Biol Blood Marrow Transplant· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia.
Jaroslaw P Maciejewski, Elaine M Sloand, Olga Nunez, Carol Boss, Neal S Young

Blood· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.
Alexa B Kimball, Tatsuyoshi Kawamura, Krupali Tejura, Carol Boss, Ana R Hancox

Arch Dermatol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis